These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 20143458)

  • 1. Is the control of dietary cholesterol intake sufficiently effective to ameliorate nonalcoholic fatty liver disease?
    Enjoji M; Nakamuta M
    World J Gastroenterol; 2010 Feb; 16(7):800-3. PubMed ID: 20143458
    [TBL] [Abstract][Full Text] [Related]  

  • 2. NPC1L1 inhibitor ezetimibe is a reliable therapeutic agent for non-obese patients with nonalcoholic fatty liver disease.
    Enjoji M; Machida K; Kohjima M; Kato M; Kotoh K; Matsunaga K; Nakashima M; Nakamuta M
    Lipids Health Dis; 2010 Mar; 9():29. PubMed ID: 20222991
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel role of NPC1L1 in the regulation of hepatic metabolism: potential contribution of ezetimibe in NAFLD/NASH treatment.
    Yoshida M
    Curr Vasc Pharmacol; 2011 Jan; 9(1):121-3. PubMed ID: 21044016
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ezetimibe as a potential treatment for non-alcoholic fatty liver disease: is the intestine a modulator of hepatic insulin sensitivity and hepatic fat accumulation?
    Ahmed MH; Byrne CD
    Drug Discov Today; 2010 Aug; 15(15-16):590-5. PubMed ID: 20601094
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ezetimibe improves high fat and cholesterol diet-induced non-alcoholic fatty liver disease in mice.
    Zheng S; Hoos L; Cook J; Tetzloff G; Davis H; van Heek M; Hwa JJ
    Eur J Pharmacol; 2008 Apr; 584(1):118-24. PubMed ID: 18329014
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of long-term ezetimibe therapy in patients with nonalcoholic fatty liver disease.
    Park H; Shima T; Yamaguchi K; Mitsuyoshi H; Minami M; Yasui K; Itoh Y; Yoshikawa T; Fukui M; Hasegawa G; Nakamura N; Ohta M; Obayashi H; Okanoue T
    J Gastroenterol; 2011 Jan; 46(1):101-7. PubMed ID: 20658156
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The efficacy of ezetimibe on nonalcoholic fatty liver disease (NAFLD)].
    Shiwa T; Kawanami Y; Yokoyama T; Moritani A; Hashimoto M; Gotoh T
    Nihon Shokakibyo Gakkai Zasshi; 2011 Aug; 108(8):1383-92. PubMed ID: 21817841
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Niemann-Pick C1 like 1 (NPC1L1) inhibitor ezetimibe improves metabolic disease via decreased liver X receptor (LXR) activity in liver of obese male mice.
    Sugizaki T; Watanabe M; Horai Y; Kaneko-Iwasaki N; Arita E; Miyazaki T; Morimoto K; Honda A; Irie J; Itoh H
    Endocrinology; 2014 Aug; 155(8):2810-9. PubMed ID: 24773344
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ezetimibe improves liver steatosis and insulin resistance in obese rat model of metabolic syndrome.
    Deushi M; Nomura M; Kawakami A; Haraguchi M; Ito M; Okazaki M; Ishii H; Yoshida M
    FEBS Lett; 2007 Dec; 581(29):5664-70. PubMed ID: 18022391
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ezetimbe as potential treatment for cholesterol gallstones: the need for clinical trials.
    Ahmed MH
    World J Gastroenterol; 2010 Apr; 16(13):1555-7. PubMed ID: 20355232
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term combination therapy of ezetimibe and acarbose for non-alcoholic fatty liver disease.
    Nozaki Y; Fujita K; Yoneda M; Wada K; Shinohara Y; Takahashi H; Kirikoshi H; Inamori M; Kubota K; Saito S; Mizoue T; Masaki N; Nagashima Y; Terauchi Y; Nakajima A
    J Hepatol; 2009 Sep; 51(3):548-56. PubMed ID: 19596472
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nutritional investigation of non-obese patients with non-alcoholic fatty liver disease: the significance of dietary cholesterol.
    Yasutake K; Nakamuta M; Shima Y; Ohyama A; Masuda K; Haruta N; Fujino T; Aoyagi Y; Fukuizumi K; Yoshimoto T; Takemoto R; Miyahara T; Harada N; Hayata F; Nakashima M; Enjoji M
    Scand J Gastroenterol; 2009; 44(4):471-7. PubMed ID: 19058085
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of insulin-sensitizing agents in combination with ezetimibe, and valsartan in rats with non-alcoholic fatty liver disease.
    Assy N; Grozovski M; Bersudsky I; Szvalb S; Hussein O
    World J Gastroenterol; 2006 Jul; 12(27):4369-76. PubMed ID: 16865780
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of intestinal cholesterol absorption by ezetimibe is a novel therapeutic target for fatty liver.
    Yamagishi S; Nakamura K; Matsui T; Sato T; Takeuchi M
    Med Hypotheses; 2006; 66(4):844-6. PubMed ID: 16188393
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ezetimibe prevents hepatic steatosis induced by a high-fat but not a high-fructose diet.
    Ushio M; Nishio Y; Sekine O; Nagai Y; Maeno Y; Ugi S; Yoshizaki T; Morino K; Kume S; Kashiwagi A; Maegawa H
    Am J Physiol Endocrinol Metab; 2013 Jul; 305(2):E293-304. PubMed ID: 23715726
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effects of ezetimibe on non-alcoholic fatty liver disease and glucose metabolism: a randomised controlled trial.
    Takeshita Y; Takamura T; Honda M; Kita Y; Zen Y; Kato K; Misu H; Ota T; Nakamura M; Yamada K; Sunagozaka H; Arai K; Yamashita T; Mizukoshi E; Kaneko S
    Diabetologia; 2014 May; 57(5):878-90. PubMed ID: 24407920
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of ezetimibe on NAFLD.
    Averna M
    Atheroscler Suppl; 2015 Feb; 17():27-34. PubMed ID: 25659874
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of ezetimibe on hepatic fat, inflammatory markers, and apolipoprotein B-100 kinetics in insulin-resistant obese subjects on a weight loss diet.
    Chan DC; Watts GF; Gan SK; Ooi EM; Barrett PH
    Diabetes Care; 2010 May; 33(5):1134-9. PubMed ID: 20185740
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A human-type nonalcoholic steatohepatitis model with advanced fibrosis in rabbits.
    Ogawa T; Fujii H; Yoshizato K; Kawada N
    Am J Pathol; 2010 Jul; 177(1):153-65. PubMed ID: 20489159
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ezetimibe reduces fatty acid quantity in liver and decreased inflammatory cell infiltration and improved NASH in medaka model.
    Oishi T; Terai S; Kuwashiro S; Fujisawa K; Matsumoto T; Nishina H; Sakaida I
    Biochem Biophys Res Commun; 2012 May; 422(1):22-7. PubMed ID: 22554516
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.